Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sedana Medical secures data exclusivity and market protection for Sedaconda[®] (isoflurane) until 2031

Sedana Medical AB (publ) announces that the European Medicines Agency’s Paediatric Committee has issued a positive opinion regarding the compliance with the company’s Paediatric Investigation Plan. This confirms data exclusivity and market protection for Sedana Medical’s Sedaconda[®] (isoflurane) until 2031.In 2021, Sedana Medical’s proprietary pharmaceutical Sedaconda (isoflurane) received its first market authorization in Europe for administration via the medical device Sedaconda ACD for inhaled sedation of mechanically ventilated patients in intensive care. As part of the approval,

Findity Revolutionizes Expense Management with the Launch of Expense API

Findity, the leading provider of expense management technology, is proud to announce the launch of its revolutionary solution, the Expense API. This groundbreaking technology empowers businesses to leverage Findity's platform and seamlessly integrate tailored expense management functionality into their existing software suites.Findity’s Expense API allows companies to directly embed expense management capabilities into their apps and web clients, avoiding the significant time and costs required to develop such functionality from scratch. The Expense API provides direct access to Findity’

Eevia Health Plc Interim Report Q3 - 2023

Significant events during the third quarter of 2023:Net sales1 decreased by 20% from KEUR 1 148 in Q3-22 to KEUR 917 in Q3-23. Compared to the second quarter this year, Net sales decreased by 54%, from KEUR 1 985. The gross profit in Q3-23 landed at KEUR 347, a decrease of 52% from KEUR 725 in Q3-22 and down 70% from KEUR 1 352 in Q2-23. The gross margin2 was 38% in Q3-23, down from 63% in Q3-22 and 68% in Q2-23. The decrease since the previous quarters is due to a changing product mix. There was no effect on gross margin from side-stream products in Q3-23. EBITDA in Q3-23 was KEUR 2

Panoro Energy – Invitation to Third Quarter 2023 Results Presentation

Oslo, 22 November 2023 - The third quarter 2023 trading and financial update to be announced on Wednesday 29 November will be available on our website http://www.panoroenergy.com at 07:30 a.m. CET. The company will hold a live webinar presentation at 09:00 a.m. CET on Wednesday 29 November 2023, during which management will discuss the results and operations, followed by a Q&A session. The webinar presentation can be accessed through registering at the link below and the online event will be equipped with features to ask live questions. Joining instructions for participating online or

Desert Control releases its Q3 2023 Report and Year-to-Date Company Update

Desert Control concluded the third quarter with a strengthened financial position and continued consistent execution. The successful Q3 capital raise and the preceding strategic review secured more than NOK 100M in additional liquidity to support the company’s commercialization phase through the first half of 2025. Sandnes, Norway, 22 November 2023 – Desert Control AS (DSRT) announces its third quarter report for the fiscal period ending 30 September 2023. Q3 2023 Highlights · Completed a capital raise of NOK 67.50 million, solidifying the company’s financial runway through H1-

Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation

Company Announcement Nanoform Finland Plc November 22, 2023 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation Project Blockbuster is progressing well. The clinical manufacture of nanoformed material for the project has been done and our partner has successfully made tablets. The clinical trials are expected to start before year end and the results are expected in 1Q24. If the results are positive, the targeted timeline for one or several license/commercial

Gjensidige Forsikring Capital Markets Day 2023: Releasing the full potential

Gjensidige Forsikring hosts its Capital Markets Day today at 09:00 CET. Presentations will be held by Geir Holmgren, Chief Executive Officer of Gjensidige, and key members of the Group executive management team. The presentations will provide a review of the Group's strategy and goals, as well as operational priorities and the Group's strong capabilities.  - I am proud to present new and more ambitious financial targets, and to confirm sustainability targets in line with the Paris agreement. I am certain that our strong capabilities will enable us to release the full potential in

Heatcube successfully passed Power Market Test to provide flexibility services to the Danish electricity market

Oslo, Norway, 22 November 2023 - Kyoto Group is thrilled to announce that the Heatcube at Norbis Park (Nordjylland Power Station) in Aalborg, Denmark, has passed the Power Market Test required to provide flexibility services to the electricity market in the DK1 grid area.By proving a fast and reliable charging response, Kyoto’s Heatcube at Norbis Park successfully passed the Power Market Test required to qualify for participation in the balancing market in DK1. This will enable Nordjylland Power Station to utilize the aFRR and mFRR market to minimize the price of electricity, which

Everfuel – Q3 2023: Executing strategy realignment and progressing HySynergy 1 towards start-up

Herning, 22 November 2023 – Everfuel A/S today published its third quarter 2023 financial results. Key events · Everfuel and Hy24 signs JV agreement for green hydrogen infrastructure in the Nordics · JV completes HySynergy 1 acquisition as first investment under the EUR 200 million framework · Implementing realigned strategy focused on scaling green hydrogen production and Alternative Fuels Infrastructure Regulation (AFIR) ready heavy duty hydrogen mobility solutions · HySynergy 1 progressing according to updated timeline with expected start up in Q1 2024 supported by fully

SAS receives court approval to enter into investment agreement in its exit financing solicitation process

SAS announces that the U.S. Bankruptcy Court for the Southern District of New York (the “Court”) has approved SAS’ entry into the investment agreement with the winning bidder consortium in SAS’ exit financing solicitation process. The winning bidder consortium consists of Castlelake, L.P., on behalf of certain funds or affiliates (“Castlelake”), Air France-KLM S.A. and Lind Invest ApS, together with the Danish state (collectively, the “Investors”).On November 4, 2023, SAS announced that it had entered into an investment agreement with the Investors, subject to approval by the Court. The

Nordea Bank Abp: Repurchase of own shares on 21.11.2023 and technical correction to an earlier release

Nordea Bank AbpStock exchange release – Changes in company’s own shares21.11.2023 at 22.50 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 21.11.2023 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |72,491 |10.34 |749,506.20

Elos Medtech applies for de-listing from Nasdaq Stockholm

The board of directors of Elos Medtech has today resolved to apply for de-listing of the Company’s shares from Nasdaq Stockholm as a result of TA Associates, through EM Intressenter AB (“EM Intressenter”), controlling more than 90 percent of the shares in Elos Medtech AB (publ) (“Elos Medtech” or the “Company”), today having initiated compulsory redemption of the remaining shares in the Company. EM Intressenter has informed the board of directors of Elos Medtech that EM Intressenter initiates compulsory redemption of the remaining shares in Elos Medtech and requested that the shares in

InDex Pharmaceuticals discontinues cobitolimod phase III program

· Independent Data Monitoring Committee (DMC) advises that cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1 · More information regarding next steps will be provided once a thorough analysis of the data from Induction Study 1 has been completed 21 November, 2023 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announces that an independent DMC has completed the planned dose selection analysis including safety review and assessment for futility in Induction Study 1 of the phase III program CONCLUDE. The DMC advises that

EM Intressenter AB initiates compulsory redemption proceedings

EM Intressenter AB (“EM Intressenter”), holding approximately 94.3 percent of the shares and approximately 83.6 percent of the votes in Elos Medtech (“Elos Medtech” or the “Company”), has today initiated compulsory redemption of the remaining shares in Elos Medtech. Elos Medtech will notify the minority shareholders that compulsory redemption has been requested and that the minority shareholders will have the opportunity to, no later than two weeks from the date of the notification, in writing report that they wish to bring their own action and state a joint arbitrator. If shareholders to

Buy-back of shares in MTG during week 46, 2023

During the period between 13 November and 17 November 2023 Modern Times Group MTG AB (publ) (LEI code 549300E8NDODRSX29339) (“MTG”) repurchased, in total, 169,433 own class B shares (ISIN code SE0018012494) under the share repurchase program initiated by the Board of Directors to deliver shareholder value and to optimize the capital structure of the company.The share buy-backs form a part of the share repurchase program of a maximum of 6,283,278 shares for a maximum amount of SEK 300 million, which MTG announced on 1 September 2023. The share repurchase program, which runs from 4 September

Symrise has purchased an additional 800,000 shares in Swedencare at up to SEK 58.50 – will compensate those who accepted the mandatory public offer

Press release21 November 2023 On 5 June 2023, Symrise AG (“Symrise”) announced a mandatory public offer to the shareholders of Swedencare AB (publ) (“Swedencare”) at SEK 37.50 per share (the “Offer”). The acceptance period for the Offer commenced on 21 June 2023 and expired on 26 July 2023. As announced on 28 July 2023, the Offer was accepted by shareholders with a total of 270,521 shares in Swedencare, corresponding to a total of 0.17 percent of the share capital and votes in Swedencare. On 3 August 2023, it was announced that Symrise had acquired additional shares in Swedencare at

Multiconsult ASA - Share buyback

Multiconsult ASA (OSE: MULTI) announced on 5 July 2023 a non-discretionary agreement with ABG Sundal Collier for the repurchase of up to 500 000 of its ordinary shares in the market with employee share saving programme and executive management bonus schemes, or as consideration in connection with acquisitions.From 13 - 21 November 2023, Multiconsult ASA has purchased a total of 14 100 own shares at Oslo Børs at an average price of NOK 120.5040 per share.  Aggregated overview of transactions per day: Overview oftransactionsDate Aggregated daily Weighted average

Transaction in Own Shares

FIDELITY JAPAN TRUST PLC TRANSACTION IN OWN SHARES The Board of Fidelity Japan Trust PLC ("the Company") announces that on 21 November 2023 the Company bought into Treasury 225,000 of its own shares at a price of 171.1800 pence per share.  The Company's issued ordinary share capital is 136,161,695 of which 8,337,086 shares are held in Treasury, which attract no voting rights. Therefore, the total number of voting rights in the Company is now 127,824,609. The above figure (127,824,609) may be used by shareholders as the denominator for the calculations by which they will

Toivo Group Plc: Certified Adviser change

Company release, 21th November 2023 at 19:00 p.m. The shares of Toivo Group Plc are listed for trading on Nasdaq First North Growth Market Finland, which requires nominating a Certified Adviser. Effective 1 January 2024, the Certified Adviser to Toivo Group Plc is Nordic Certified Adviser. Danske Bank A/S, Finland Branch, is the Certified Adviser to Toivo Group Plc until the 31st of December 2023. Further informationMarkus MyllymäkiCEOToivo Group PlcTel. +358 (0)40 847 6206markus.myllymaki@toivo.fi Certified Adviser: Danske Bank A/S, Finland branch, +358 (0)50 575 4422

Third quarter results 2023

Fornebu, 21[st] November 2023, Ocean Yield AS (“Ocean Yield” or the “Company”)announces results for the third quarter 2023. Highlights · EBITDA for Q3 2023 was USD 51.5 million and adjusted for lease effects was USD 79.0 million. · Net profit for Q3 2023 was USD 18.5 million. · Strong balance sheet, with an equity ratio of 30.6% and USD 133.8 million in cash. · During the third quarter, the Company signed an agreement to acquire four LR1 newbuilding product tankers with sustainability-linked long-term bareboat charters to Braskem S.A. · Also during the quarter, the

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB0003328555 Issuer Name Fidelity Japan Trust PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details of person subject to the notification obligation Name City of London Investment Management Company Limited City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from the person(s)

#23-100 Decision on delisting of Anima Group AB from Nordic SME

Nordic Growth Market NGM AB (”NGM”) has decided to delist the shares in Anima Group AB (“the Company”) from Nordic SME. According to 2.2.10 in the Nordic SME Rulebook, the composition of the board of directors must be such that it is sufficiently competent to manage and control a listed company. Furthermore, according to 3.3.2, the exchange may decide to delist the shares if the company fails to pay applicable fees despite repeated reminders. Since the Company no longer fulfils the listing requirements regarding the Company’s organization and has failed to pay applicable fees, the shares

There are no items matching the current filter
There are no more items matching the current filter
Back to top